Caspase-3 activity in LCL8664 cells treated with IL-6 and/or TGF-β1. LCL8664 cells were treated with IL-6 (20 ng/ml), TGF-β1 (1 ng/ml), both, or were untreated (untr) for 16 or 24 hours. Parallel samples were treated with the broad caspase inhibitor, zVAD-fmk (zVAD) as a negative control. Caspase-3 activity was quantified in whole cell lysates using a colorimetric assay. The data are reported as fold-change in caspase-3 activity relative to untreated samples.